In 1997, the first published reports highlighted PPAR
as a novel cancer therapeutic target regulating differentiation of cancer cells. A subsequent flurry of papers described these activities more widely and fuelled further enthusiasm for differentiation therapy, as the ligands for the PPAR were seen as well tolerated and in several cases well-established in other therapeutic contexts.
This initial enthusiasm and promise was somewhat tempered by contradictory findings in several murine cancer models and equivocal trial findings. As more understanding has emerged in recent years, a renaissance has occurred in targeting PPAR within the context of either chemoprevention or chemotherapy.
This clarity has arisen in part through a clearer understanding of PPAR biology, how the receptor interacts with other proteins and signaling events, and the mechanisms that modulate its transcriptional actions. Equally greater translational understanding of this target has arisen from a clearer understanding of in vivo murine cancer models. Clinical exploitation will most likely require precise and quantifiable description of PPAR actions, and resolution of which targets are the most beneficial to target combined with an understanding of the mechanisms that limits its anticancer effectiveness.
1. Current Understanding of PPARγ Biology
1.1. PPARγ is a Transcription Factor
The human PPARγ was cloned in 1994 and subsequently two murine isoforms were identified in
mouse: gamma-1 and gamma-2, resulting from the use of different initiator
methionines [1, 2]. Subsequently, at least three isoforms
have been identified in humans with common expression in adipocytes and the
large intestine and more restricted isoform expression in other tissues [3]. PPARγ
plays a key role in energy metabolism and differentiation (reviewed in [4–7]); and reflecting this, the murine PPAR γ−/− is embryonically lethal, and if rescued,
the animal lacks normal adipocytes [8].
PPARγ is a phylogenetic member of subfamily 1
the nuclear receptor (NR) superfamily and shares a number of generic
mechanistic features in common with other subgroup members, including the
retinoic acid receptors (RARs), vitamin D receptor (VDR), farnesoid X receptor
(FXR), and liver X receptors (LXRs). These receptors are most commonly located
in the nucleus and heterodimerize with one of three retinoid X receptor (RXR)
subtypes, to bind specific response elements in target gene regulatory regions.
Crystallization studies of PPARγ bound with RXRα proved pivotal for deciphering the
basis for heterodimerization with RXR for multiple NRs [9].
The presence of ligand changes the receptor confirmation and also influences
choice of association with either coactivator (CoA) or corepressor (CoR)
complexes. In the absence of
ligand, NR heterodimers are contained within multimeric complexes (2.0 MDa)
containing CoRs (e.g., NCOR1) [10]. Also, within these complexes is a
range of enzymes, which act to modify the posttranslational status of histone
tails and maintain a locally closed repressive chromatin environment, for
example, histone deacetylases (HDAC), such as HDAC3 and SIRT1 [10–15].
Ligand activation shifts receptor conformation and distribution to enhance interaction with CoA
complexes. A large number of interacting CoA proteins have been described, which can be divided into
multiple families including the NCOA/SRC family and members of the large
bridging mediator complex including PPARγ binding protein (PBP/MED1) complex [16, 17]. Through the latter, the NR receptor
complex links to the cointegrators CBP/p300 and basal transcriptional
machinery. For example, PPARγ is known to associate with proteins, such as SRC-1, PGC1-α, CARM1, and a battery of histone
modifying enzymes, such as histone acetyltransferases (HAT), which together
initiate and promote transactivation [18–22].
The complex choreography of these events is a very active area of research, being
at a crossroads of several important areas in contemporary biology, such as
multimeric protein complex assembly and chromatin remodeling. Transcription
involves cyclical rounds of promoter-specific complex assembly, gene
transactivation, complex disassembly, and proteosome-mediated receptor
degradation [23–25].
1.2. Newly Characterized and Unique Features of PPARγ
Outside of these general characteristics, uncertainty and ambiguity remain in
constructing a predicative schema for understanding PPARγ function and signaling in cancer
biology. Some of the uncertainties arise due to a number of structural and
regulatory variations of PPARγ outside the core features of NRs,
thereby leading to apparently pleiotropic actions. Compounding these
difficulties is the issue of studying PPARγ signaling in cancer biology, which is
intrinsically an unstable and evolving disease environment.
By contrast to a high-affinity receptor, such as estrogen receptor α (ERα),
the members of the subfamily 1 of the NR superfamily are typified by their
large ligand-binding domain and may therefore accept different ligands. The
PPARγ ligand-binding pocket has a volume of more than 1400 Å3 and
therefore can bind a wide range of different lipophilic molecules
(see Figure 1). As shown in
Figure 1, free fatty acids are
metabolized to arachidonic acid, and then through either lipooxygenase (LO) or
cyclooxygenase (COX) activities to give rise to a range of natural ligands for PPARγ. Many of these reactions are tightly
controlled such that a ligand metabolite is enzymatically generated and
cleared.
Figure 1: Generation of natural PPARγ ligands (solid
arrows = direct conversion, broken arrows = multiple step conversion.
Metabolites are indicated and some of the key regulating enzymes are shown in
boxes).
Circulating and cellular fatty acids give rise to the majority of the natural ligands for PPARγ; therefore, the PPARs in general and PPARγ
specifically form a sensing mechanism to maintain homeostasis in changing
physiological circumstances such as feeding and exercise. This capacity, as
discussed later, is implicated in a range of disease settings including cancer.
The omega 6 fatty acid, linoleic acid, is highly inflammatory and therefore
carefully controlled in vivo. It is a PPARγ ligand and, through subsequent desaturase and elongase activities, is
metabolized to arachidonic acid. A wide range of natural ligands for PPARγ
is subsequently derived through arachidonic acid metabolism. LO activity (e.g., arachidonate 5-LO
and 15-LO) generates oxidized lipids which act as PPARγ
ligands, such as 8 (S)-hydroxyeicosatetraenoic acid (8-(S)-HETE), 15-(S)-HETE,
9-hydroxy-10,12-octadecadienoicacid (9HODE), and 13-HODE.
Subsequent dehydrogenase activity, for example, of 13-HODE by 13-HODE
dehydrogenase, can result in a further series of PPARγ
ligands prior to their subsequent conversion to leuktrienes [26–28].
In parallel, arachidonic acid can be metabolized through cyclooxygenase activity (through COX-1 and -2) to
prostaglandins such as PG and subsequently PG, PG,
PG, and PG. These compounds exert a diverse range of
cellular actions, but key metabolites in these cascades appear to exert potent PPARγ
activation. PG, the product of prostaglandin D synthase (encoded
by PGDS), is able to undergo
nonenzymatic degradation to a J series prostaglandin, 15-deoxy-12,14-prostaglandin (15d-PG), which is a potent PPARγ
ligand [26, 29–33]. Similarly, metabolites of PG can activate PPARγ,
and their generation is controlled during differentiation, for example, of
adipocytes [34]. Many of these reactions appear to be regulated through classical
feedback loops, thus, the regulation of arachidonic acid metabolism to provide
prostaglandins and leukotrienes is regulated at multiples levels by the actions
of PPARγ, for example, regulation of
LOs and of COX-2 activity and several of the downstream enzymes [26, 29–35].
The discovery of synthetic ligands for this receptor has been driven by the identification of a number of significant
disease settings, in which PPARγ signaling is implicated (inflammation, metabolic disorders, and cancer). A goal
of this research is the identification of novel pharmacological compound that
display gene- and cell-selective actions [36]. The diversity of cell function, and presumably
the relatively large ligand-binding pocket, has encouraged investigators to
undertake rational screening approaches to identify a diverse panel of ligands [31, 37–51]. Indeed, novel selective compounds
frequently display differential ligand-binding pocket docking sites. Implicit,
within these discoveries is that the subtly different induced receptor
conformations allow for the different spatiotemporal associations of CoA and ancillary proteins thereby deriving
target gene specificity [40, 41, 52–55]. Thiazolidinediones (TZDs) were the
first synthetic compounds investigated as PPARγ
ligands [56]; this class also includes rosiglitazone,
pioglitazone, and troglitazone. The latter caused a severe idiosyncratic liver
problem and thus has been discontinued. The TZDs have proven to be a
breakthrough in the therapy of type II diabetes because they decrease insulin
resistance by promoting glucose uptake, mitochondrial biogenesis and fatty acid
absorption by increasingly differentiated adipocytes (reviewed in [57]).
This focus at the level of the PPARγ
ligand may be too exclusive. For example, the RXR member of this complex can
also bind simultaneously with its ligand, which can result in enhanced
transcriptional activity (6). Perhaps more importantly, the receptor structure
allows it to influence both the basal and regulated transcription levels of
target genes independent of ligand. That is, the unliganded structure of PPARγ
also exposes a number of critical amino acids on helix 12 that allows CoA
binding and may explain the high basal expression levels of PPARγ
target genes in the absence of ligand. In this regard, PPARγ
most closely resembles another xenobiotic metabolizing NR, constitutive
androstane receptor (CAR) [58]. These findings may also suggest that
the expression of CoA and CoR proteins are actually more important for
regulating gene targets than either the levels or specificity of ligands.
The biology of PPARγ is intimately associated with that of the PGC-1α CoA and a number of other cofactors.
The actions of these proteins have most clearly been described in
well-established PPARγ systems, such as adipocyte differentiation and regulation of energy metabolism. The Pgc-1α murine knockout displays abnormal
metabolic rates, temperature fluctuations, and a lethal cardiac defect [59, 60].
Reflecting its importance for regulating PPARγ function, levels of PGC-1α are tightly regulated by ubiquitination
[61].
PPARγ receptor activity is also regulated by
a cohort of posttranslational mechanisms, such as small ubiquitin-related
modifier (SUMO) process. Sumoylation of the ligand-binding domain, in the
presence of ligand, prevents the release and subsequent ubiquitination of
NCOR1, and therefore sustains the repressive action, leading to the so-called
ligand-dependent transrepression [62, 63].
This process is antagonized, by the removal of the SUMO modification by the
SUSP-1 enzyme [64]
thus establishing a dynamic level of regulation to modify the actual impact of
ligand. Furthermore, PPARγ is serine phosphorylated, for example,
in response to MAPK signaling leading to nuclear export and attenuation of
transcriptional ability [65–67].
By contrast, PBP/MED1 is regulated at multiple sites by phosphorylation to
enhance signaling by PPARγ [68].
To place the expression and regulation of PPARγ within the broader context of NR
biology, several scientists have proposed and utilized system level approaches
to dissect NR function including PPARγ. One of the most significant examples
of this approach has been the spatiotemporal profiling of all 49 murine NRs in
multiple tissues at different time points during the circadian rhythm [69, 70].
These approaches have revealed a number of provocative findings. In terms of
tissue expression, PPAR γ most closely follows Lxr α and Gr, and forms a triumvirate that is intimately implicated in the
control of inflammation. The expression of PPARγ was shown also to follow circadian
rhythm expression in white adipose tissue and the liver, but not other tissues [69, 70].
Similarly, others have shown that Pgc-1 α follows a circadian rhythm in the
liver and skeletal muscle of mice [20],
and it cooperates with other NRs to regulate additional members of the clock
family.
1.3. Transcriptional Targets of PPARγ
One approach to defining PPARγ specificity has been to describe the cohort of target genes regulated by its
actions; generally, these studies involve microarray studies in a range of cell
types including adipocytes [71] and
macrophages [72].
Commonly, a range of gene targets has been identified associated with
metabolism and transport of lipids, including lipoprotein lipase, fatty acid
binding, and transport proteins and acyl-CoA synthase. Similar approaches have
been used to study the impact of PPARγ signaling on proliferation and differentiation. For
example, in chondorosarcoma and ovarian cancer cells, PPARγ
actions were associated with changes in the ratio of BAX to BCL-2, induction of
programmed cell death [73], and
upregulation of cyclin-dependent kinase inhibitors (CDKIs), such as CDKN1A (encodes
p21(waf1/cip1)) [74]. In MCF-7 breast cancer cells PPARγ upregulated a
similar spectrum of CDKIs [75]. A number of studies have identified the
IGF axis as a target of PPARγ signaling. For example, in bone marrow cells [76], and in silico and in vitro
studies have characterized a range of PPAR response elements (PPREs) in several
insulin-like growth factor binding protein (IGFBPs) genes [77].
Other scientists have attempted to increase the accuracy of gene target
identification by using selective ligands, for example, in colorectal cells,
and identified gene targets associated with mitotic restraint and cell adhesion
[78–82]. Complimentary approaches have utilized
adenoviral transfection of receptor subtypes to identify differentially
expressed genes, confirmed with chromatin immunoprecipitation (ChIP) approaches
[83].
The accurate prediction of target genes is compounded by the highly integrated nature of PPARγ
signaling with other NR family members. For example, its activities are
mutually antagonized with ERα signaling, and appear to be cooperative with both VDR and RAR, in part by
increased retinol synthesis [84–86]. To investigate this apparent
transcriptome plasticity will require the integrations of in silico response element
identification protocols combined with ChIP-sequencing approaches to establish
specificity and redundancy; comparable approaches have been undertaken for ERα [87]. Building
towards this goal, we have undertaken a meta-analyses of PPRE sequences to
generate an algorithm to predict PPAR subtype binding and screened chromosome
19, as a test set, to identify and confirm a number of novel genes [88].
Together, these findings suggest that ligand is just one of a number of mechanisms to regulate receptor function.
Other regulatory contributions are determined by PPARγ
expression level, isoform, posttranslational modification, location, crosstalk
with functionally related receptors and cofactor expression. Together, these
components combine with wider transcriptional programs, such as energy
utilization, circadian rhythm, and the control of inflammation to drive and
specify the timing of transcriptional outputs.
2. Control of Self-Renewing Tissues
2.1. Common Cancers and Leukemia Arise in Self-Renewing Tissues
The weighted contribution of the underlying forces, acting at the levels of genes,
chromosomes, signaling cascades and tissue organization, that drive cancer
initiation and progression remain poorly understood. Historically, a paradigm
of exclusive genetic causality was the basis for investigating cancer etiology
and it identified certain key nodal points of cellular control, such as p53. In
the postgenomic era, other strong penetrance genes have not been readily
identified. The sporadic, multistage acquisition of a cancer phenotype requires
disruption of multiple mechanisms of cellular restraint and tissue organization
(reviewed in [89]). Reflecting a sporadic
multifactorial cancer phenotype, the single greatest risk factor for most
cancers is age, with the average age of onset of breast, prostate, and colon
cancer in the sixth and seventh decades of life.
Further understanding of transformation processes has arisen through appreciation of
the diverse cell types present at the sites of high-profile malignances.
Epithelial linings of the prostate and mammary glands, the gastrointestinal
tract and hematological systems all typify self-renewing tissues containing
stem cell populations [90–94].
These cells give rise to committed progenitors, and in turn the multiple-cell
lineages required for tissue function. Stem cells are relatively rare and
long-lived, but frequently quiescent. They are uniquely able to undergo
asymmetric division, to give rise to both other stem cells and transiently
amplifying populations of progenitor cells, that in turn give rise to the
differentiated cell types. The differentiated epithelial cells are functional
but short-lived and lost through programmed cell death processes, to be
replaced by newly differentiated transiently amplifying cells. Cellular control
of the intricate balance of the processes of division, differentiation, and
programmed cell death include common roles for Wnt, Hedgehog, and other
developmental signal transduction processes. Convergent targets for these
signals include key regulators of cellular proliferation, such as Myc and p21(waf1/cip1).
As a result of their long life cycle and high proliferative capacity, stem cells, rather than
their short-lived terminally differentiated daughter cells, are the candidates
for transformation. However, a range of mechanisms is in place to maintain stem
cell genomic integrity, perhaps including retention of the so-called “immortal”
DNA strand and enhanced protection mechanisms [95–103].
These controls notwithstanding, the transformation of stem cells has given rise
to the concept of cancer stem cells. Such cancer stem cells are well
established in leukemia and accumulating evidence supports the presence of
these cells in prostate, breast, and colon cancers [104–108].
2.2. Restoration of Controlled Self-Renewal as a Therapeutic Goal
Members of the NR superfamily play a number of well-established roles in the control of self-renewal and the process
of normal differentiation. For example, the AR and ERα
receptors play pivotal roles in prostate and breast tissue development and
maintenance. Distortion of some of these actions is, in turn, central to the
development of cancer in these tissues and is targeted therapeutically though
antagonism, either completely in the case of the AR, or selectively in the case
of the ERα. Agonism of other receptors has been pursued to induce differentiation and
inhibit proliferation of cancer cells. The best example of this paradigm is the
induction of remission of patients with acute promyelocytic leukemia using the
RAR ligand, all-trans retinoic acid, and also to prevent recurrence of head and neck cancers.
As a consequence of the induced terminal differentiation of normal preadipocytes by
ligands for PPARγ [1, 2], investigators were
encouraged to use TZDs to attempt to induce differentiation of human
liposarcoma cells in vivo [109]. Successes in vitro encouraged
these same physician-scientists to give troglitazone to a series of patients
with liposarcoma, which resulted in a retardation of growth and induction of
differentiation of these tumor cells. The long-term effect of TZD on
liposarcomas requires further study; nevertheless, these pioneer studies
spurred the examination of the effect of TZDs on a number of cancers both in vitro and in vivo in colon, breast, prostate,
myeloid leukemia, neuroblastoma, glioblastoma, lymphoma, lung, cervical,
bladder, head and neck, esophageal, gastric, pancreatic, and choriocarcinoma
cancers [21, 81, 110–140].
The multiple findings from studies illustrate the promise and failings of
targeted therapies toward PPARγ to restore mitotic restraint and induce
differentiation.
3. PPARγ Signaling in Cancer
3.1. Colon Cancer
To establish a role for PPARγ
to protect against the development of colon cancer, investigators have used a
range of in vivo and in vitro approaches. In murine
models, the expression of PPAR γ has been manipulated in either an environmental or a genetic background that
displays enhanced susceptibility to colonic cancer. For example, mice with
heterozygous germ-line deletions of PPAR γ have an increased proclivity to develop N-methyl-N-nitrosourea carcinogen-induced colon cancer compared
with wild-type mice, supporting a growth inhibitory role for PPAR γ. Significantly, troglitazone reduced the tumor incidence in
wild-type but not heterozygote mice [122]. By
contrast, other scientists have utilized the well-established AP model of colon cancer with apparently contradictory findings. These mice have a
germ-line mutation of the APC gene resulting in deregulated β-catenin
signaling, and a very significantly increased frequency of small and large
intestinal adenocarcinomas. Surprisingly, administration of TZD to AP mice resulted in increased frequency of colon cancers compared to control
animals [141].
Subsequently, however, generation of the intestinal specific PPAR γ−/− and AP bigenic mouse
demonstrated an unequivocal effect of PPAR γ
to suppress tumor formation and suggests that significant off-target effects of
TZD occur in mice, especially in the AP mouse colon cancer model
[142]. Off-target effects of TZD generally appear to also have broad anticancer
properties; therefore, the findings in this model appear quite unusual. For
example, PPAR γ inactive analogs of TZD initiate the proteosomic degradation of β-catenin
[143] and cyclin D1, as well as, interfering
with BAX family member interactions to bring about apoptosis [144, 145]. Nevertheless, why AP mice receiving a TZD have more colon cancers still is not fully elucidated. AP mice have high levels of PPAR γ
in the colonic cells and are inappropriately sequestrated by β-catenin
to a unique set of gene targets [146]. Interestingly, PPARα ligands inhibit polyp
formation in the AP model [118] re-enforcing the concept that
the TZD-driven enhanced tumor formation in the AP mouse is a model
artifact, or at least not general phenomena.
In humans, multiple lines of evidence support an unequivocal function for PPARγ signaling in colon cancer. Mutations of
the receptor have been reported, although rare [147], and polymorphisms are
functionally linked with an increased incidence of this cancer [148].
A range of natural and synthetic PPARγ ligands inhibit proliferation, induce
programmed cell death and exert prodifferentiation actions in vitro and in vivo, for example, when tested in human xenografts [149–151].
The potency of the ligand actions can be significantly enhanced further by
combining the treatment with RXR ligands [124, 152].
Furthermore, this signaling capacity is integrated with the control of other
proliferative signals, such as gastrin [153]
(reviewed by [154]).
3.2. Breast Cancer
The findings on breast cancer support the broad anticancer activities of PPARγ signaling, and also reflect the studies
in colon cancer. That is, generally in vitro and in vivo
studies support a clear role for this receptor to suppress proliferation,
induce differentiation and programmed cell death. In rodent models, the PPARγ agonists block N-nitroso-N-methylurea-induced
breast cancer in Sprague-Dawley rats [155]
and DMBA-induced breast cancer in mice [114].
Similarly, PPAR γ+/− mice have a greater
susceptibility to develop breast and ovarian cancers after their exposure to
7,12-dimethylbenz(a)anthracene [156].
By contrast, transgenic mice having a constitutively active PPARγ in their breast tissue crossed with the
MMTV-neu mouse model of breast cancer displayed accelerated kinetics of breast
cancer development, although the authors noted that the tumors surprisingly were more secretory and differentiated in nature [157]. Similar to the AP model, this
tumor model depends on deregulated Wnt activity, and the authors suggested that the effects
may also reflect aberrant interplay between PPARγ and Wnt signaling.
Human breast cancer cells express PPARγ [158] and can be targeted, for
example, with TZD, and a range of other PPARγ ligands to induce differentiation and
inhibition of cell growth both in vitro and in xenograft models, effects which can be enhanced by
cotreatment with either retinoids, TGFβ or TNFα [110, 111, 113, 114, 130, 158–163].
For example, PPARγ ligands plus selective retinoid ligands
converge on targets, such as RARβ, which is known to act as a tumor
suppressor and is commonly silenced in malignancy [164]. Similarly, PPARγ activation results in upregulation of
E-cadherin and thereby redistribution of β-catenin [130].
Natural ligands, such as dietary fatty acids, change expression in syndecan-1
with an impact on cytoskeleton structure and the induction of apoptosis [165]. Furthermore, 15d-PG inhibits ERα signaling in a PPARγ-independent manner by covalent
modification of the receptor [166].
PPARγ expression is a favorable prognostic factor [167]
and associates with ERα positive disease [75].
A note of caution, however, phase II trials of TZDs in women with hormone
refractory metastatic breast cancer were equivocal [168].
3.3. Prostate Cancer
The biology of the prostate is intimately associated with the synthesis of prostaglandins, as
suggested by the name. These growth regulatory factors are readily secreted by the gland [169] and give rise to the H and D series prostaglandins and 15d-PG.
Equally, the biology of the prostate is associated with the metabolism of fatty
acids 15S-HETE [33]. Therefore, the prostate
seems a tissue where PPARγ may play a strong role in governing cell growth and
differentiation. For example, signals derived from PGDS activity in the adjacent stroma, such as PG,
activate PPARγ, and control epithelial proliferation [170].
PPARγ actions in prostate cancer cell lines [171]
and primary cancer models [120] are well documented and include the induction of type
II programmed cell death also known as autophagy [112].
These studies encouraged several groups to undertake clinical trials with PPARγ ligands and disease stabilization was
reported [115].
Again in this disease setting, PPARγ-independent actions of TZDs were apparently identified, which were
nonetheless potent anticancer signals [172, 173].
Set against these findings, the Evans team used a prostate cancer, the TRAMP model, to demonstrate that PPAR γ heterozygote mice have no change in disease
progression compared to wild-type litter mates [174].
3.4. Leukemia and Lymphoma
Previously, we showed that human myeloid
and lymphoid leukemia cells express PPARα and PPARγ; ligands, such as troglitazone, inhibited their cell growth [139, 175]. This antiproliferative effect was
markedly enhanced in the presence of various retinoids. Also, macrophages and
myelomonocytic leukemic cells express abundant PPARγ (73), and PPARγ ligands can induce acute myelomonocytic leukemic cells (THP-1) to
differentiate toward macrophages with an increased expression of the CD36
scavenger receptors, as well as other surface markers associated with
differentiation including CD11b, CD14, and CD18 (73). Studies by others and us
have also shown that PPARγ ligands can inhibit growth and/or induce apoptosis of Hodgkin’s disease
[139] and multiple myeloma cells [176, 177]. The mechanism, by which PPARγ ligand inhibits the proliferation of malignant hematopoietic cells, is
not totally clear. Some of the antileukemic effects of PPARγ may be independent of the PPARγ receptor. Furthermore, we have found that a dual PPARα/γ ligand (TZD18) has the ability to induce marked apoptosis and to
inhibit growth of lymphoid leukemia cells [178]. In general, the effect of PPARγ ligands on myeloid leukemic growth and differentiation is modest (74).
3.5. Mechanisms of Resistance
Genetically, the PPARγ generally appears to retain its
integrity. Rare mutations have been reported and more recently dominant
negative variants of the receptor were identified although the biological
impact remains to be established firmly [179].
Similarly, altered isoforms may be overexpressed in cancer [180–183].
Cytogenetic rearrangement has been identified in follicular thyroid cancer
fusing the PAX-8 transcription factor to PPARγ. In vitro studies suggest
PAX-8-PPARγ acts in a dominant negative fashion toward wild-type PPARγ [184]
(Figure 2).
Figure 2: The actions of the PPARγ to regulate target genes are highly
choreographed, being influenced by many factors. This is reflected by the
multiple mechanisms that distort PPARγ signaling in cancer. PPARγ-RXR heterodimer binds to specific
response elements contained within upstream, intronic, and downstream sequences
of target genes. The ability of this heterodimer to participate in either
transactivation or transrepression is disrupted by multiple mechanisms in
cancer cells. (1) Genetic mechanisms; although
relatively rare, mutations to the PPARG gene occur, as do cytogenetic rearrangements, notably in thyroid cancer with
the generation of the PAX-8-PPARγ fusion product. (2) Epigenetic mechanisms; the PPARγ receptor normally exists in a dynamic
equilibrium with each of two large complexes, namely, coactivator (CoA) and
corepressor (CoR) complexes to regulate genes targets. Central components of
these complexes are a cohort of ancillary proteins that act to regulate a
cohort of posttranslational modifications (PTMs) to histone tails and thereby
determine local chromatin organization. In cancer, the stochiometry of this
equilibrium is disrupted with downregulation of CoA components such as PGC1-α and upregulation of CoR components such
as NCOR1. The net result is the distortion of gene regulation abilities, most
likely in a promoter specific manner. (3) Posttranslational mechanisms; PPARγ is regulated by a number of
posttranslational modification including sumoylation, which can allow the
liganded receptor to retain associations with the CoR complex and bring about
ligand-dependent transrepression. The enzymes responsible for this activity
appear altered in malignancy suggesting that the levels of sumoylated PPARγ are in turn distorted. In parallel,
associated cofactors, such as PBP/Med1, are also regulated by PTMs and further
manipulate and PPARγ signaling. (4) Nuclear receptor network dynamics; the PPARγ is a member of a highly interactive
network of receptors and in malignancy these interactions appear distorted. For
example, the ERα (E) homodimer is able to repress the PPARG promoter, and equally PPARγ is both coexpressed with, and regulates
expression of other receptors such as PPARα, LXRs, FXR, and VDR to coordinate
transcriptional programs. (5) Ligand
generation; PPARγ senses a wide panel of lipophilic
ligands many of which are derived from and catabolized downstream of metabolism
of arachidonic acid. Key steps include generation of fatty acids, which are PPARγ ligands, through lipooxygenase (LO)
activity (e.g., 5-LO). To counterbalance these activities, the generation of
prostaglandins is mediated in large part through the actions of cyclooxygenase
(COX) activity (e.g., COX-2). While this can also give rise to PPARγ ligands, these effects are protected
further by the clearance of potent prostaglandin PPARγ ligands by the actions of enzymes, such
as AKR1C3. In malignancy, an inversion of COX-2 to 5-LO occurs, and further
protection from generation of potent prostaglandin ligands occurs, for example,
through upregulation of AKR1C3. (6) Dominant
transcriptional programs; the actions of the PPARγ appear to be distorted as a consequence
of deregulated dominant transcriptional programs, such as Wnt signaling. These
effects are mediated by enhanced β-catenin (β) levels and include sequestration of PPARγ to β-catenin responsive genomic regions.
Implicit within this is that there is a high degree of plasticity of PPARγ signaling and that transcriptional
signals can be placed within a quantifiable hierarchy.
In parallel to these genetic changes, the actions of PPARγ appear to be attenuated by changes
in receptor expression and known cofactors. The range of interactions with partner proteins
of PPARγ appears to be altered. Interactions
with PGC1-α are reduced in several cancers [21, 185, 186];
and oppositely the known CoRs associated with PPARγ are overexpressed and the
transcriptional actions of PPARγ are repressed by epigenetic mechanisms
involving HDAC3 [187–189].
Equally, the control of posttranslational modifications appears to be altered. SUSP-1 [64],
which removes the SUMO mark (required for ligand-dependent transrepression)
appears to be downregulated in a number of breast and prostate cancers [190]. Within the NR network, PPARγ is coexpressed and interacts both positively
and negatively with a cohort of other receptors. For example, the ERα and Cyclin D1, (itself a well-known ERα target gene and CoA) can both repress
the PPARγ gene promoter [191, 192].
The natural ligands for PPARγ are diverse and it is more challenging
to make definitive statements concerning their altered generation in
malignancy. Equally, the ability for PPARγ to act in a significant and
ligand-independent manner also reduces, to an extent, the significance of
ligand levels. These considerations aside, the patterns of ligand generation
for PPARγ appear to be altered in malignancy. The
balance between LO and COX-2 is dysregualted to favor generation of PGH
production [193] and accompanied by
downregulation of PPARγ [194].
This causes an elevation of PG, which in turn is converted to
protumorigenic prostaglandins, such as PG, through other
synthases. The levels of PG, which gives rise to 15-PG,
are closely regulated by an aldo-ketoredcutase (AKR1C3) that is upregulated in
malignancy [195–199].
An emergent area of distortion is the extent to which PPARγ
signaling is at the mercy of more dominant signal transduction and transcriptional
programs. The two tumor promotion models associated with signaling by PPARγ
involved elevated levels of signaling by the Wnt pathway. These findings
combined with observations on the diversity of genes regulated by the receptor
suggest that PPARγ signaling displays plasticity in terms of exact promoter choice. Gene
regulatory options are distilled by the combination of receptor-associating
cofactors and other signal transduction events. For example, overwhelming Wnt
signaling pulls PPAR γ to β-catenin gene targets [146]. This plasticity of signaling is probably reflected by the
fact that complete loss or mutation of PPARγ in malignancy is relatively rare. Rather, expression is retained but probably
sequestrated and distorted by more dominant signaling events. Resolving these
interactions will require a quantitative and hierarchical understanding of the
signaling paths through which PPARγ combines with other NRs and signal transduction events to
regulate cell fates.
4. Is PPARγ a Ligand-Activated Tumor Suppressor?
A tumor suppressor can be characterized as a protein that reduces the probability that a cell in a metazoan
will undergo transformation. Initiation and progression of cancer are
associated with attenuation, corruption, expression, and protein function of
tumor suppressor genes, increasing the likelihood of tumor formation.
Approximately 10 years have past since the first few reports of PPARγ
exerting anticancer cellular effects [109, 111]. Taken together the overwhelming body of data suggests that
PPARγ can behave as a ligand-activated tumor suppressor.(1)PPARγ ligands through activating PPARγ can inhibit proliferation and induce
differentiation and apoptosis of a wide range of neoplastic cell types in vitro and in murine xenograft
tumor models.(2)PPAR γ−/− mice are more susceptible than wild-type mice to mammary, colon, ovarian, and
skin tumors after exposure to carcinogens and enhance tumor formation in some
genetic models of cancer, for example, AP model of colon cancer.(3)The actions of these receptors are attenuated in malignancy by genetic,
cytogenetic, and epigenetic mechanisms, and ligand generation is compromised. Set against, these data are two findings of enhanced tumor formation related to
PPARγ in murine cancer models. TZD enhances
tumor formation in the AP model [141] and the bigenic mice
overexpressing PPARγ in the MMTV-neu breast cancer model
have more, highly differentiated tumors [157].
In retrospect, these high-profile studies perhaps reveal important facts of the
dominant relationship between Wnt signaling over PPARγ in the mouse. This understanding may
have important implications for the necessary molecular diagnostics required to
target PPARγ therapies most effectively.
5. Future Directions
5.1. Exploiting Dietary Understanding from Chemoprevention
Recently, the appreciation of the impact of diet on either the initiation or progression of
cancer has come significantly to the fore. The World Health Organization has
now stated that after smoking diet forms the most preventable cause of cancer.
Aspects of these relationships are found in breast, prostate, and colon cancer,
where the rate of initiation and progression of disease may be influenced both
positively and negatively by the cumulative impact of dietary factors over an
individual’s lifetime. Beyond the specific micro and macronutrient constituents,
the energetic status of an individual is emerging as a risk factor with
increased calorific intake and decreased energy expenditure, both contributing
deleteriously to cancer initiation and progression (reviewed in [200]).
The NR network has emerged as a systemic sensor of lipid and energetic status [201]. This capacity includes
components for sensing carbohydrates [202, 203],
cholesterol homeostasis through LXRs and FXR, regulation of metabolic rate
through TRs, and sensing of diverse lipids by PPARs. Crosstalk within the
superfamily ensures that these sensing and regulatory functions integrate with
other receptors such as those for sex steroids. Multiple aspects of these
relationships are observed in cancer. For example, fatty acids, such as those present in fish oil and a
range of other dietary factors, can activate PPARγ and are associated
with in vivo prevention of colon cancer in
mouse models [165, 204–206]
and in human trials in breast
cancer [207]. Equally, convergence on PPARs and VDR to regulate IGFBPs
and other negative regulatory components of the AKT signaling cascade [208] provides attractive targets
for therapeutic intervention.
To exploit this, understanding in either dietary guidelines for the general population or as a
chemoprevention strategy for groups defined at risk (e.g., by age or molecular
diagnostic) is highly demanding. Despite the significance and potential
clinical benefit of these relationships, it remains unclear the critical time frame
and dose range when dietary factors may be protective against cancer development,
for example, during embryogenesis, childhood, or adult life. By comparison,
considerable resources were required to elucidate what is now established as a
clear causal relationship between cigarette smoke and lung cancer [209]. There are reasons to be
encouraged in targeting PPARγ in a chemoprevention context as studies
on the consequences of long-term usage TZDs in diabetes patients have revealed
a protective benefit against lung cancer [210].
To address the impact of diet on disease, the emerging field of nutrigenomics aims to dissect
the impact of dietary factors on genomic regulation, and thereby physiology and
pathophysiology, utilizing a range of postgenomic technologies [211, 212].
This level of integration is emerging. For instance, PPARγ polymorphisms recently have been shown
to play a role in determining cancer susceptibility only when patients are
above a certain body mass index threshold [213]. Exploitation of such
understanding will require modeling of these functions in a network context (reviewed
in [214, 215]). Most likely, the application of such rational
approaches will resolve the significance of PPARs to mediate anticancer actions
of potent dietary factors, such as conjugated linoleic acid [130, 216].
5.2. PPARγ and the Regulation of Cellular Energetics
A number of deleterious side effects occur through the use of fatty acids as an energy store, including the
generation of reactive oxygen species as a result of lipid peroxidation. The
PPAR family combines roles in lipid sensing and utilization with cellular
protection against lipid excess. Specifically, PPARγ
plays a role in fatty acid uptake and transport (e.g., by adipocytes) and acts
to control inflammation that can arise from increased adipocyte differentiation
and proliferation (reviewed in [217, 218]). These actions are all altered in malignancy. As proposed
by Otto Warburg in the 1930s (and summarized later [219]), cancer cells derive their energy
increasingly from anaerobic glycolysis; this concept has received renewed
support in recent years [220–222]. The altered energetics of cancer cells are common events,
and cancer patients frequently display symptoms which in many ways mimic type
II diabetes [223]. Associated with many of these events is
an increased propensity for local inflammation.
PPARγ therapeutics have been explored within these separate arenas in different
disease settings. That is, to regulate fatty acid metabolism and insulin
resistance within the metabolic syndrome, to suppress inflammation, for
example, in colitis models [224], and to promote mitotic restraint and
induce differentiation within cancer cells. These functions are not separated,
but rather all distorted within malignancy. The fact that PPARs, in general,
and PPARγ specifically play an integrated regulatory role in these processes suggests
that new avenues of exploitation will require a more detailed and quantitative
understanding of the contribution of PPAR signaling against a tissue and whole
body background of inflammation and altered cellular energetics.
5.3. Ongoing Questions
The current challenges in PPARγ cancer biology include the following.(1)Determine at which stage PPARγ can influence normal tissue
self-renewal.(2)Understand in cancer systems which
combination of critical cellular processes to exploit: exert mitotic restraint,
induce differentiation, regulate local inflammation, and impact on cellular
energetic processes.(3)Define to what extent conformationally
restricted synthetic ligands (the so-called SPARMS [225]) can regulate target of these
cellular processes through selective cohorts of PPARγ target genes.(4)Identify the mechanisms that attenuate,
manipulate, dissociate, and redirect PPARγ signaling in cancer cells and address
to what extent the proteins involved in these processes are drugable
therapeutic targets.(5)Reveal whether this understanding can be best
exploited in the setting of either chemoprevention and/or chemotherapy.(6)Quantify, model, and predict to what
extent PPARγ is a nodal point within the NR network
and other signal transduction process. Establish hierarchies that place PPARγ specifically, and NRs generally, in the
context of other signal processes that collectively maintain homeostasis.
Abbreviations| APC: | Adenomatous polyposis coli |
| AR: | Androgen receptor |
| CAR: | Constitutive androstane receptor |
| CDKI: | Cyclin-dependent kinase inhibitors |
| ChIP: | Chromatin immunoprecipitation |
| CoA: | Coactivator |
| CoR: | Corepressor |
| COX: | Cyclooxygenase |
| DMBA: | 7,12-dimethylbenz[a] anthracene |
| ERα: | Estrogen receptor α |
| FXR: | Farnesoid X receptor |
| GR: | Glucocorticoid receptor |
| HAT: | Histone acetyltransferase |
| HDAC: | Histone deacetylase |
| HETE: | Hydroxyeicosatetraenoic acid |
| HODE: | Hydroxyoctadecadienoic acid |
| IGFBP: | Insulin-like growth factor binding protein |
| LXR: | Liver X receptor |
| NCOA/SRC: | nNuclear receptor coactivator/steroid receptor coactivator |
| NCOR1: | Nuclear corepressor |
| NR: | Nuclear receptor |
| P: | Prostaglandin |
| PBP/MED1: | PPARγ binding protein/mediator 1 |
| PGC1-α: | Peroxisome proliferator-activated receptor γ coactivator 1 α |
| PPARγ: | Peroxisome proliferator-activated receptor γ |
| PSA: | Prostate specific antigen |
| RAR: | Retinoic acid receptor |
| RXR: | Retinoid X receptor |
| SIRT: | Sirtuin 1 |
| SUMO: | Small ubiquitin-related modifier |
| TCF: | T-cell factor |
| TNF: | Tumor necrosis factor |
| TR: | Thyroid receptor |
| TZD: | Thiazolidinedione |
| VDR: | Vitamin D receptor |
| 15d-PG: | 15-deoxy-12,14-prostaglandin . |
Acknowledgments
Moray J. Campbell acknowledges support of the BBSRC Agri-Foods panel, UK. Carsten Carlberg acknowledges
support of the Academy of Finland and the Fonds National de Recherche (Luxembourg). Moray J. Campbell and Carsten Carlberg acknowledge the support of NucSys, a European Community FP6-funded consortium aimed at the
dissection and mathematical modeling of nuclear receptor responses to
nutritional signals in health and disease. H. Phillip Koeffler acknowledges support of NIH grants. The
author is a member of the Jonsson Cancer Center,
University of California, Los Angeles, and has the endowed Mark Goodson
Chair in Oncology Research at Cedars-Sinai Medical Center. The authors declare that there is no conflict
of interest that would prejudice the impartiality.